Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens

Details for Australian Patent Application No. 2010210422 (hide)

Owner Tokai Pharmaceuticals

Inventors Casebier, David

Agent Cullens

Pub. Number AU-A-2010210422

PCT Pub. Number WO2010/091306

Priority 61/150,031 05.02.09 US

Filing date 5 February 2010

Wipo publication date 12 August 2010

International Classifications

C07J 43/00 (2006.01) Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton

A61K 31/58 (2006.01) - containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

18 August 2011 PCT application entered the National Phase

  PCT publication WO2010/091306 Priority application(s): WO2010/091306

25 August 2011 Corrigenda

  PCT applications that have entered the National Phase - Name Index Under the name Tokai Pharmaceuticals, Application No. 2010210422, under INID (71) correct the name to Tokai Pharmaceuticals, Inc. Specifications Republished The following specifications contained errors when advertised OPI, Accepted or Certified. They have been reissued on the AU-A or AU-B CD-ROM of this Journal date. 2004279800 Vertex Pharmaceuticals Incorporated 2005225117 Multisteps Pty Ltd 2005230881 Eli Lilly and Company 2008317693 Mits

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010210426-Inhibitors of Jun N-terminal kinase

2010210408-Process for preparing poly(trimethylene ether) glycol and copolymers thereof